Transporter and metabolizer gene polymorphisms affect fluoroquinolone pharmacokinetic parameters

doi:10.3389/fphar.2022.1063413

Review

. 2022 Dec 12:13:1063413.

doi: 10.3389/fphar.2022.1063413. eCollection 2022.

Transporter and metabolizer gene polymorphisms affect fluoroquinolone pharmacokinetic parameters

Nurul Annisa^{1

2}, Melisa I Barliana^{1

3}, Prayudi Santoso⁴, Rovina Ruslami⁵

Affiliations

¹ Department of Biological Pharmacy, Biotechnology Pharmacy Laboratory, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.
² Unit of Clinical Pharmacy and Community, Faculty of Pharmacy, Universitas Mulawarman, Samarinda, Indonesia.
³ Center of Excellence for Pharmaceutical Care Innovation, Universitas Padjadjaran, Sumedang, Indonesia.
⁴ Division of Respirology and Critical Care, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran-Hasan Sadikin Hospital, Bandung, Indonesia.
⁵ Division of Pharmacology and Therapy, Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.

PMID: 36588725
PMCID: PMC9798452
DOI: 10.3389/fphar.2022.1063413

Review

Transporter and metabolizer gene polymorphisms affect fluoroquinolone pharmacokinetic parameters

Nurul Annisa et al. Front Pharmacol. 2022.

. 2022 Dec 12:13:1063413.

doi: 10.3389/fphar.2022.1063413. eCollection 2022.

Authors

Nurul Annisa^{1

2}, Melisa I Barliana^{1

3}, Prayudi Santoso⁴, Rovina Ruslami⁵

Affiliations

¹ Department of Biological Pharmacy, Biotechnology Pharmacy Laboratory, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.
² Unit of Clinical Pharmacy and Community, Faculty of Pharmacy, Universitas Mulawarman, Samarinda, Indonesia.
³ Center of Excellence for Pharmaceutical Care Innovation, Universitas Padjadjaran, Sumedang, Indonesia.
⁴ Division of Respirology and Critical Care, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran-Hasan Sadikin Hospital, Bandung, Indonesia.
⁵ Division of Pharmacology and Therapy, Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.

PMID: 36588725
PMCID: PMC9798452
DOI: 10.3389/fphar.2022.1063413

Abstract

Tuberculosis (TB) is an infectious disease that occurs globally. Treatment of TB has been hindered by problems with multidrug-resistant strains (MDR-TB). Fluoroquinolones are one of the main drugs used for the treatment of MDR-TB. The success of therapy can be influenced by genetic factors and their impact on pharmacokinetic parameters. This review was conducted by searching the PubMed database with keywords polymorphism and fluoroquinolones. The presence of gene polymorphisms, including UGT1A1, UGT1A9, SLCO1B1, and ABCB1, can affect fluoroquinolones pharmacokinetic parameters such as area under the curve (AUC), creatinine clearance (C_Cr), maximum plasma concentration (C_max), half-life (t_1/2) and peak time (t_max) of fluoroquinolones.

Keywords: ABCB1; SLCO1B1; UGT1A1; UGT1A9; moxifloxacin; pharmacogenetics; sitafloxacin; trovafloxacin.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

**FIGURE 1**
Fluoroquinolones pharmacokinetic parameter affected by gene polymorphisms.

See this image and copyright information in PMC

Cited by

Pharmacogenetics and Pharmacokinetics of Moxifloxacin in MDR-TB Patients in Indonesia: Analysis for ABCB1 and SLCO1B1.
Annisa N, Afifah NN, Santoso P, Yunivita V, Te Brake LHM, Aarnoutse RE, Barliana MI, Ruslami R. Annisa N, et al. Antibiotics (Basel). 2025 Feb 16;14(2):204. doi: 10.3390/antibiotics14020204. Antibiotics (Basel). 2025. PMID: 40001447 Free PMC article.
Pharmacokinetics, pharmacodynamics, and safety of ciprofol emulsion in Chinese subjects with normal or impaired renal function.
Tao J, Liu S, Zhao YY, Qi L, Yan P, Wu N, Liu X, Liu D, Tian X. Tao J, et al. Front Pharmacol. 2023 Nov 23;14:1260599. doi: 10.3389/fphar.2023.1260599. eCollection 2023. Front Pharmacol. 2023. PMID: 38074142 Free PMC article.
Fluoroquinolones and Biofilm: A Narrative Review.
Geremia N, Giovagnorio F, Colpani A, De Vito A, Botan A, Stroffolini G, Toc DA, Zerbato V, Principe L, Madeddu G, Luzzati R, Parisi SG, Di Bella S. Geremia N, et al. Pharmaceuticals (Basel). 2024 Dec 11;17(12):1673. doi: 10.3390/ph17121673. Pharmaceuticals (Basel). 2024. PMID: 39770514 Free PMC article. Review.
The Impact of Genetic Polymorphisms on the Anti-Hyperglycemic Effect of Dapagliflozin.
Wang Z, Li X, Xu Q, Yao Y, Li X, Yan H, Lv Q. Wang Z, et al. Diabetes Metab Syndr Obes. 2024 Jul 31;17:2881-2894. doi: 10.2147/DMSO.S464671. eCollection 2024. Diabetes Metab Syndr Obes. 2024. PMID: 39100970 Free PMC article.

References

1. Almazroo O. A., Miah M. K., Venkataramanan R. (2017). Drug metabolism in the liver. Clin. Liver Dis. 21, 1–20. 10.1016/j.cld.2016.08.001 - DOI - PubMed
1. Balram C., Sabapathy K., Fei G., Khoo K. S., Lee E. J. D. (2002). Genetic polymorphisms of UDP-glucuronosyltransferase in asians: UGT1A1*28 is a common allele in Indians. Pharmacogenetics 12 (1), 81–83. 10.1097/00008571-200201000-00012 - DOI - PubMed
1. Belle D. J., Singh H. (2008). Genetic factors in drug metabolism. Am. Fam. Physician 77 (11), 1553–1560. - PubMed
1. Belmonte C., Ochoa D., Roman M., Saiz-Rodriguez M., Wojnicz A., Gomez-Sanchez C. I., et al. (2018). Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 polymorphisms on pharmacokinetics and safety of aripiprazole in healthy volunteers. Basic Clin. Pharmacol. Toxicol. 122 (6), 596–605. 10.1111/bcpt.12960 - DOI - PubMed
1. Cardoso A. R., Queliconi B. B., Kowaltowski A. J. (2010). Mitochondrial ion transport pathways: Role in metabolic diseases. Biochim. Biophys. Acta 1797 6 (7), 832–838. 10.1016/j.bbabio.2009.12.017 - DOI - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources

[1] Almazroo O. A., Miah M. K., Venkataramanan R. (2017). Drug metabolism in the liver. Clin. Liver Dis. 21, 1–20. 10.1016/j.cld.2016.08.001 - DOI - PubMed

[2] Almazroo O. A., Miah M. K., Venkataramanan R. (2017). Drug metabolism in the liver. Clin. Liver Dis. 21, 1–20. 10.1016/j.cld.2016.08.001 - DOI - PubMed

[3] Balram C., Sabapathy K., Fei G., Khoo K. S., Lee E. J. D. (2002). Genetic polymorphisms of UDP-glucuronosyltransferase in asians: UGT1A1*28 is a common allele in Indians. Pharmacogenetics 12 (1), 81–83. 10.1097/00008571-200201000-00012 - DOI - PubMed

[4] Balram C., Sabapathy K., Fei G., Khoo K. S., Lee E. J. D. (2002). Genetic polymorphisms of UDP-glucuronosyltransferase in asians: UGT1A1*28 is a common allele in Indians. Pharmacogenetics 12 (1), 81–83. 10.1097/00008571-200201000-00012 - DOI - PubMed

[5] Belle D. J., Singh H. (2008). Genetic factors in drug metabolism. Am. Fam. Physician 77 (11), 1553–1560. - PubMed

[6] Belle D. J., Singh H. (2008). Genetic factors in drug metabolism. Am. Fam. Physician 77 (11), 1553–1560. - PubMed

[7] Belmonte C., Ochoa D., Roman M., Saiz-Rodriguez M., Wojnicz A., Gomez-Sanchez C. I., et al. (2018). Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 polymorphisms on pharmacokinetics and safety of aripiprazole in healthy volunteers. Basic Clin. Pharmacol. Toxicol. 122 (6), 596–605. 10.1111/bcpt.12960 - DOI - PubMed

[8] Belmonte C., Ochoa D., Roman M., Saiz-Rodriguez M., Wojnicz A., Gomez-Sanchez C. I., et al. (2018). Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 polymorphisms on pharmacokinetics and safety of aripiprazole in healthy volunteers. Basic Clin. Pharmacol. Toxicol. 122 (6), 596–605. 10.1111/bcpt.12960 - DOI - PubMed

[9] Cardoso A. R., Queliconi B. B., Kowaltowski A. J. (2010). Mitochondrial ion transport pathways: Role in metabolic diseases. Biochim. Biophys. Acta 1797 6 (7), 832–838. 10.1016/j.bbabio.2009.12.017 - DOI - PubMed

[10] Cardoso A. R., Queliconi B. B., Kowaltowski A. J. (2010). Mitochondrial ion transport pathways: Role in metabolic diseases. Biochim. Biophys. Acta 1797 6 (7), 832–838. 10.1016/j.bbabio.2009.12.017 - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Transporter and metabolizer gene polymorphisms affect fluoroquinolone pharmacokinetic parameters

Affiliations

Transporter and metabolizer gene polymorphisms affect fluoroquinolone pharmacokinetic parameters

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

Related information

LinkOut - more resources

Full Text Sources